Brought to you by 
Vivus draws down net $48.9mm of potential $110mm nondilutive financing from Pharmakon
13 Sep 2018
Executive Summary
BioPharma Secured Investments III Holdings Cayman LP, a Pharmakon Advisors-managed fund, is loaning up to $110mm to Vivus Inc. (therapeutics for obesity, sleep apnea, diabetes, and sexual health) in a “synthetic capped royalty financing.”
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Nonconvertible Debt
- Other
- Private Placement
- Royalty Sale
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Vivus draws down net $48.9mm of potential $110mm nondilutive financing from Pharmakon
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice